Omnicare Drugs India Profile
Key Indicators
- Authorised Capital ₹ 500.00 Cr
as on 07-07-2024
- Paid Up Capital ₹ 296.97 Cr
as on 07-07-2024
- Company Age 7 Year, 8 Months
- Last Filing with ROC 31 Mar 2019
- Open Charges ₹ 142.80 Cr
as on 07-07-2024
- Revenue 3165.73%
(FY 2019)
- Profit 566.79%
(FY 2019)
- Ebitda -685.87%
(FY 2019)
- Net Worth 252.57%
(FY 2019)
- Total Assets 252.06%
(FY 2019)
About Omnicare Drugs India
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2019. It's a company limited by shares with an authorized capital of Rs 500.00 Cr and a paid-up capital of Rs 296.97 Cr.
The company currently has active open charges totaling ₹142.80 Cr.
Suresh Nandiraju, Menachery Ittyrah, and Bavaguthu Shetty serve as directors at the Company.
- CIN/LLPIN
U74999TG2017PTC116303
- Company No.
116303
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
03 Apr 2017
- Date of AGM
30 Sep 2019
- Date of Balance Sheet
31 Mar 2019
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Omnicare Drugs India?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Suresh Nandiraju  | Director | Current | |
| Menachery Ittyrah | Director | Current | |
| Bavaguthu Shetty | Nominee Director | 03-Apr-2017 | Current |
Financial Performance and Corporate Structure Insights of Omnicare Drugs India.
Omnicare Drugs India Private Limited, for the financial year ended 2019, experienced significant growth in revenue, with a 3165.73% increase. The company also saw a substantial improvement in profitability, with a 566.79% increase in profit. The company's net worth Soared by an impressive increase of 252.57%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Omnicare Drugs India?
In 2019, Omnicare Drugs India had a promoter holding of 100.00%. The company had 2 Subsidiaries. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Nmc Healthcare India Private LimitedActive 8 years 25 daysMenachery Ittyrah and Bavaguthu Shetty are mutual person
Brs Health And Research Institute Private LimitedActive 8 years 3 monthsBavaguthu Shetty is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 11 Dec 2018 | ₹142.80 Cr | Open |
How Many Employees Work at Omnicare Drugs India?
Omnicare Drugs India has a workforce of 7 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Omnicare Drugs India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Omnicare Drugs India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
